ATE346154T1 - G-beta-gamma regulierte phosphatidylinositil-3' kinase - Google Patents

G-beta-gamma regulierte phosphatidylinositil-3' kinase

Info

Publication number
ATE346154T1
ATE346154T1 AT97931459T AT97931459T ATE346154T1 AT E346154 T1 ATE346154 T1 AT E346154T1 AT 97931459 T AT97931459 T AT 97931459T AT 97931459 T AT97931459 T AT 97931459T AT E346154 T1 ATE346154 T1 AT E346154T1
Authority
AT
Austria
Prior art keywords
proteins
kinase
enzyme
protein
subunit
Prior art date
Application number
AT97931459T
Other languages
English (en)
Inventor
Len Stephens
Phillip T Hawkins
Sylvia Braselmann
Original Assignee
Onyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharma Inc filed Critical Onyx Pharma Inc
Application granted granted Critical
Publication of ATE346154T1 publication Critical patent/ATE346154T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT97931459T 1996-06-27 1997-06-26 G-beta-gamma regulierte phosphatidylinositil-3' kinase ATE346154T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/672,211 US5874273A (en) 1996-06-27 1996-06-27 G-beta-gamma regulated phosphatidylinositol-3' kinase

Publications (1)

Publication Number Publication Date
ATE346154T1 true ATE346154T1 (de) 2006-12-15

Family

ID=24697610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97931459T ATE346154T1 (de) 1996-06-27 1997-06-26 G-beta-gamma regulierte phosphatidylinositil-3' kinase

Country Status (12)

Country Link
US (6) US5874273A (de)
EP (2) EP0939821B1 (de)
JP (1) JP4240537B2 (de)
CN (1) CN1306576A (de)
AT (1) ATE346154T1 (de)
AU (1) AU722324B2 (de)
CA (1) CA2259143C (de)
DE (1) DE69736983T2 (de)
DK (1) DK0939821T3 (de)
ES (1) ES2278392T3 (de)
PT (1) PT939821E (de)
WO (1) WO1997049818A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200777B1 (en) * 1997-09-01 2001-03-13 Smithkline Beecham Plc Human p101 polynucleotides
US6238886B1 (en) * 1998-02-16 2001-05-29 Smithkline Beecham Plc Compounds
WO1999041384A1 (en) * 1998-02-16 1999-08-19 Smithkline Beecham Plc Splice variants of p101 protein
WO2000011143A1 (en) 1998-08-24 2000-03-02 Smithkline Beecham Plc Human phosphatidylinositol 3-kinase regulatory p101 subunit (ec 2.7.1.137)
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
GB9903416D0 (en) * 1999-02-15 1999-04-07 Smithkline Beecham Plc Novel compounds
GB9908897D0 (en) 1999-04-19 1999-06-16 Smithkline Beecham Plc Novel compounds
WO2001028680A2 (en) * 1999-10-20 2001-04-26 Gentra Systems, Inc. Mixing and pouring apparatus with rotatable arm and related vessel
IL135310A0 (en) * 2000-03-28 2001-05-20 Compugen Ltd Novel nucleic acid and amino acid sequences
US20020164576A1 (en) * 2000-09-22 2002-11-07 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US20030044803A1 (en) * 2000-09-22 2003-03-06 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
EP1395677B1 (de) * 2001-06-11 2006-03-29 Applied Research Systems ARS Holding N.V. Szintillationsproximitätstests für aminoglycosid bindende moleküle
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
US6933246B2 (en) * 2002-06-14 2005-08-23 Trikon Technologies Limited Dielectric film
CA2491555C (en) * 2002-07-10 2012-09-11 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
US8569229B2 (en) 2008-02-07 2013-10-29 The Children's Hospital Of Philadelphia Compositions and methods which modulate G-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis
AU2009212142A1 (en) * 2008-02-07 2009-08-13 The Children's Hospital Of Philadelphia Compositions and methods which modulate G-protein signaling for the treatment of asthma
JP2013006772A (ja) * 2009-10-14 2013-01-10 Hokkaido Univ ウイルスの感染を抑制する物質のスクリーニング方法およびウイルス感染抑制剤
WO2012173984A2 (en) * 2011-06-13 2012-12-20 Albert Einstein College Of Medicine Of Yeshiva University Gβγ BINDING SITE ON THE PIK3CB GENE PRODUCT AND METHODS OF USE
CN108559715A (zh) * 2018-04-19 2018-09-21 西南大学 筛选与G蛋白βγ二聚体相互作用蛋白质的酵母转化子及其筛选方法
WO2022261136A1 (en) * 2021-06-07 2022-12-15 Flagship Pioneering Innovations Vii, Llc Compositions and methods for targeted delivery of therapeutic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208135D0 (en) * 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5885777A (en) * 1994-10-13 1999-03-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Cloning, expression and characterization of a novel form of phosphatidylinositol-3-kinase

Also Published As

Publication number Publication date
CA2259143A1 (en) 1997-12-31
US6017763A (en) 2000-01-25
US5856133A (en) 1999-01-05
WO1997049818A3 (en) 1998-02-26
JP2000511062A (ja) 2000-08-29
US5856132A (en) 1999-01-05
EP0939821A2 (de) 1999-09-08
AU722324B2 (en) 2000-07-27
JP4240537B2 (ja) 2009-03-18
DE69736983T2 (de) 2007-07-26
EP0939821B1 (de) 2006-11-22
EP1676918A2 (de) 2006-07-05
AU3508397A (en) 1998-01-14
WO1997049818A2 (en) 1997-12-31
CN1306576A (zh) 2001-08-01
DK0939821T3 (da) 2007-03-26
PT939821E (pt) 2007-02-28
EP1676918A3 (de) 2006-07-12
US5869271A (en) 1999-02-09
CA2259143C (en) 2010-05-18
US5874273A (en) 1999-02-23
DE69736983D1 (de) 2007-01-04
US5859201A (en) 1999-01-12
ES2278392T3 (es) 2007-08-01

Similar Documents

Publication Publication Date Title
ATE346154T1 (de) G-beta-gamma regulierte phosphatidylinositil-3' kinase
Hammonds Jr et al. Bone-inducing activity of mature BMP-2b produced from a hybrid BMP-2a/2b precursor
Weiss et al. Receptor activation of G proteins
Jackson et al. Heat shock induces the release of fibroblast growth factor 1 from NIH 3T3 cells.
Smith et al. Identification of a potent Xenopus mesoderm-inducing factor as a homologue of activin A
Lopez et al. Unusual topogenic sequence directs prion protein biogenesis
DE69837996D1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
ATE442385T1 (de) Interleukin-17 rezeptor-ähnliches protein
WO1998031806A3 (en) Fc receptors and polypeptides
DE69333776D1 (de) Dna codierend für den menschlichen 5-ht 1f rezeptor und ihre verwendung
DE69636437D1 (de) Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung
WO1996022371A3 (en) C-C CHEMOKINE RECEPTOR 3: CKP-3 OR Eos-L2
EP1015468A4 (de) Follistatin-3
DK0746332T3 (da) DNA, som koder for en human neuropeptid Y/peptid YY/pankreas-polypeptidreceptor (Y4), samt anvendelse deraf
AR008077A1 (es) Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector.
DE69637599D1 (de) Rezeptoren für das humane Interleukin-12
DE69333623D1 (de) Klonierung und expression von gonadotropinreleasing hormon
ATE540965T1 (de) Ob-rezeptor und verfahren zur diagnose und behandlung von gewicht
EP1496364A3 (de) Klonierung und Expression von Gonadotropinreleasing Hormone rezeptor
DE69333284D1 (de) Polypeptide mit serotoninerger (5ht5a) rezeptor-aktivität, für sie kodierende nukleinsäuren und ihre verwendung
WO1999050298A9 (en) GFRα-X, A NOVEL GLIAL-DERIVED NEUROTROPHIC FACTOR RECEPTOR AND USES THEREFOR
Hatakeyama et al. Fgr expression restricted to subpopulation of monocyte/macrophage lineage in resting conditions is induced in various hematopoietic cells after activation or transformation
WO2002002599A3 (en) HUMAN G PROTEIN-COUPLED RECEPTOR IGPcR17, AND USES THEROF
French et al. A population of Thy-1 molecules associated with the cytoskeleton
Ruble et al. Molecular characterization of a new member of the immunoglobulin superfamily that potentially functions in T-cell activation and development

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0939821

Country of ref document: EP